Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|TAS-115||MET Inhibitor 51 VEGFR2 Inhibitor 35||TAS-115 is a small molecule inhibitor of MET and KDR (VEGFR2), which may lead to angiogenesis blockade and tumor regression (PMID: 24140932, PMID: 31820255).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KDR positive||pancreatic cancer||sensitive||TAS-115||Preclinical||Actionable||In a preclinical study, pancreatic islet endothelial cells were sensitive to TAS-115, resulting in decreased phosphorylation of Vegfr2, and inhibition of cell growth and angiogenesis in culture and mouse models (PMID: 24140932).||24140932|
|Unknown unknown||Advanced Solid Tumor||not applicable||TAS-115||Phase I||Actionable||In a Phase I trial, TAS-115 was well tolerated and deemed safe, and resulted in some preliminary efficacy in patients with advanced solid tumors (J Clin Oncol (Meeting Abstracts) May 2015 vol. 33 no. 15_suppl 2532).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|